No Data
No Data
The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why
Iovance Biotherapeutics: A Strong Buy on Robust Clinical Data and Market Potential
HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics with a Buy and maintains $32 price target.
Iovance Biotherapeutics' Lifileucel Shows Promising Phase 2 Results: A Strong Buy Recommendation
Analysts Conflicted on These Healthcare Names: Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals Inc (AMLX) and Vaxcyte (PCVX)
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo